A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study

Investigational New Drugs

Volumn 24, Issue 6, 2006, Pages 515-520

  Whitehead, Robert P ^a   McCoy, Sheryl ^b   Rivkin, Saul E ^c   Gross, Howard M ^d   Conrad, Marcel E ^e   Doolittle, Gary C ^f   Wolff, Robert A ^g   Goodwin, J Wendall ^h   Dakhil, Shaker R ⁱ   Abbruzzese, James L ^g  

^a University of Texas Medical Branch School of Medicine   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d Dayton Clinical Oncology Program   (United States)

^e Gulf Coast Minority Based Clinical Oncology Program   (United States)

^f UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS   (United States)

^h Ozarks Regional Community Clinical Oncology Program   (United States)

ⁱ WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

Author keywords

Epothilone B analogue; Ixabepilone; Pancreas cancer; Phase II; Southwest Oncology Group

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; CREATININE; EPOTHILONE B; IXABEPILONE; TROPONIN T;

ABDOMINAL CRAMP; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BRAIN ISCHEMIA; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; DEATH; DEHYDRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DUODENUM ULCER; DYSPHAGIA; DYSPNEA; EMBOLISM; ESOPHAGITIS; FATIGUE; FEMALE; FLU LIKE SYNDROME; GRANULOCYTOPENIA; HEADACHE; HEMATOCHEZIA; HUMAN; HYPERKALEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; INFECTION; INTESTINE OBSTRUCTION; KIDNEY FAILURE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; METASTASIS; MUSCLE WEAKNESS; NAUSEA; NEUROPATHIC PAIN; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RECTUM HEMORRHAGE; RECURRENT CANCER; STOMATITIS; THROMBOSIS; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; EPOTHILONES; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 33747689092     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-8440-x     Document Type: Article

References (17)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ (2004) Cancer Statistics, 2004. CA A Cancer J Clin 54:8-29
2. Evans DB, Abbruzzese JL, Willett CG (2001) Cancer of the pancreas. Section 4 of Chapter 33.4, Cancers of the Gastrointestinal Tract. In DeVita VT Jr., Hellman S, Rosenberg SA (eds), Cancer Principles and Practice of Oncology, 6th edn, Lippincott Williams & Wilkins, Philadelphia, pp. 1126-1161
3. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413
4. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG (1994) Phase II trial of gemcitabine (2′, 2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12:29-34
5. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, Blatter J (1996) Phase II study of gemcitabine in patients with advanced cancer. British J Cancer 73:101-105
6. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R (1999) An investigational new drug treatment program for patients with gemcitabine. Cancer 85:1261-1268
7. Louvet C, Labianca R, Hammel P, Lledo G, de Braud F, Andre T, Cantore M, Ducreux M, Zaniboni A, de Gramont A (2004) GemOx (gemcitabine+oxaliplatin) versus gem (gemcitabine) in non resectable pancreatic adenocarcinoma: Final results of the GERCOR/GISCAD intergroup phase III. J Clin Oncol 22 (No 14S) p 315s abstract #4008, (2004 ASCO Meeting Proceedings (Post meeting edition)
8. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Stoffregen C, Clemens M (2003) A phase III trial comparing gemcitabine plus cisplatin vs gemcitabine alone in advanced pancreatic carcinoma. Proceedings ASCO 22: 250, # 1003 (abstract)
9. Rocha Lima CM, Green MR, Rotche R, Miller Jr WH, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776-3783
10. Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss GR, Macdonald JS (1997) Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: A Southwest Oncology Group study. J Clin Oncol 15:2414-2419
11. Lee FYF, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA (2001) BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429-1437
12. Mani S, McDaid H, Hamilton A, Hochster A, Cohen MB, Khabelle D, Griffin T, Lebwohl DE, Liebes L, Muggia F, Horwitz SB (2004) Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 10:1289-1298
13. Whitehead RP, McCoy SA, Rivkin SE, Gross HM, Conrad ME, Abbruzzese JL. (2004) A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) in patients with advanced pancreas cancer: A Southwest Oncology Group Study. Proceedings ASCO 23: p 315, #4012 (abstract)
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate response to treatment in solid tumors. J Nat Cancer Inst 92:205-216
15. rd, Giguere JK, Abbruzzese JL (2005) A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest Oncology Group (SWOG-9924) study. Invest New Drugs 23:485-487
16. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL (2004) Cetuximab, a monoclonal antibody targeting the epidermal growth factor recptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter Phase II trial. J Clin Oncol 22:2610-2616
17. Kindler HL, Friberg G, Stadler WM, Singh DA, Locker G, Nattam S, Kozloff M, Kasza K, Vokes EE (2004) Bevacizumab (B) plus gemcitabine (G) in patients (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center Phase II trial. Proceedings ASCO 23:314, #4009 (abstract)